To identify new druggable targets/pathways in UM we are performing a synthetic lethal CRISPR/Cas9 screen with CRISPR sub-libraries targeting either the kinome or the epigenome.
In addition we are trying to identify differences in phosphorylation status of proteins between primary and metastasis cell lines by mass-spectrometry approach (in collaboration with Vertegaal lab).
Furthermore, we are investigating the oncogenic functions of the p53-regulator Mdmx, which is highly expressed in ~40% of UM. An interesting new link between Mdmx and FOXO family members has recently been elucidated and is being further pursued.
Inhibition of interaction of Mdmx/Mdm2 with p53 (and p73?) is a therapeutic option for UM, which is being investigated.